A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity

Journal of Controlled Release

Volumn 173, Issue 1, 2014, Pages 158-165

  Song, Ying Chyi ^a   Cheng, Han Yin ^a   Leng, Chih Hsiang ^a,b   Chiang, Sheng Kuo ^a   Lin, Chih Wei ^a   Chong, Pele ^a,b   Huang, Ming Hsi ^a   Liu, Shih Jen ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adjuvant; Cervical cancer; CpG oligodeoxynucleotide; Human papillomavirus (HPV); Immunotherapy

Indexed keywords

ALIPHATIC COMPOUNDS; CYTOLOGY; DISEASES; EMULSIFICATION; EPITOPES; MAMMALS; NANOPARTICLES; OLIGONUCLEOTIDES; ONCOGENIC VIRUSES; PEPTIDES; POLYETHYLENE GLYCOLS; TUMORS;

ADJUVANT; CERVICAL CANCERS; HUMAN PAPILLOMAVIRUS; IMMUNOTHERAPY; OLIGODEOXYNUCLEOTIDES;

T-CELLS;

CPG OLIGODEOXYNUCLEOTIDE; PEPTIDE VACCINE; POLYMER; SORBITAN TRIOLEATE; SQUALENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; SECRETORY CELL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TUMOR IMMUNITY; TUMOR REGRESSION; UTERINE CERVIX CANCER;

ADJUVANT; CERVICAL CANCER; CPG OLIGODEOXYNUCLEOTIDE; HUMAN PAPILLOMAVIRUS (HPV); IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EMULSIONS; FEMALE; HEXOSES; HUMAN PAPILLOMAVIRUS 16; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYESTERS; SQUALENE; UTERINE CERVICAL NEOPLASMS;

EID: 84888319887     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.10.027     Document Type: Article

References (68)

1. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J. Snijders, J. Peto, C.J. Meijer, and N. Munoz Human papilloma virus is a necessary cause of invasive cervi (Pubitemid 29406813)
2. J. Paavonen, D. Jenkins, F.X. Bosch, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, D.L. Apter, H.C. Kitchener, X. Castellsague, N.S. de Carvalho, S.R. Skinner, D.M. Harper, J.A. Hedrick, U. Jaisamrarn, G.A. Limson, M. Dionne, W. Quint, B. Spiessens, P. Peeters, F. Struyf, S.L. Wieting, M.O. Lehtinen, and G. Dubin Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2007 2161 2170 (Pubitemid 46977438)
3. J. Paavonen, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, D. Apter, H. Kitchener, X. Castellsague, J.C. Teixeira, S.R. Skinner, J. Hedrick, U. Jaisamrarn, G. Limson, S. Garland, A. Szarewski, B. Romanowski, F.Y. Aoki, T.F. Schwarz, W.A. Poppe, F.X. Bosch, D. Jenkins, K. Hardt, T. Zahaf, D. Descamps, F. Struyf, M. Lehtinen, and G. Dubin Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314
4. B. Romanowski, P.C. de Borba, P.S. Naud, C.M. Roteli-Martins, N.S. De Carvalho, J.C. Teixeira, F. Aoki, B. Ramjattan, R.M. Shier, R. Somani, S. Barbier, M.M. Blatter, C. Chambers, D. Ferris, S.A. Gall, F.A. Guerra, D.M. Harper, J.A. Hedrick, D.C. Henry, A.P. Korn, R. Kroll, A.B. Moscicki, W.D. Rosenfeld, B.J. Sullivan, C.S. Thoming, S.K. Tyring, C.M. Wheeler, G. Dubin, A. Schuind, T. Zahaf, M. Greenacre, and A. Sgriobhadair Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years Lancet 374 2009 1975 1985
5. The FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N. Engl. J. Med. 356 2007 1915 1927
6. S.M. Garland, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.M. Harper, S. Leodolter, G.W. Tang, D.G. Ferris, M. Steben, J. Bryan, F.J. Taddeo, R. Railkar, M.T. Esser, H.L. Sings, M. Nelson, J. Boslego, C. Sattler, E. Barr, and L.A. Koutsky Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N. Engl. J. Med. 356 2007 1928 1943 (Pubitemid 46740303)
7. N. Munoz, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.R. Brown, L.A. Koutsky, E.H. Tay, P.J. Garcia, K.A. Ault, S.M. Garland, S. Leodolter, S.E. Olsson, G.W. Tang, D.G. Ferris, J. Paavonen, M. Steben, F.X. Bosch, J. Dillner, W.K. Huh, E.A. Joura, R.J. Kurman, S. Majewski, E.R. Myers, L.L. Villa, F.J. Taddeo, C. Roberts, A. Tadesse, J.T. Bryan, L.C. Lupinacci, K.E. Giacoletti, H.L. Sings, M.K. James, T.M. Hesley, E. Barr, and R.M. Haupt Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women J. Natl. Cancer Inst. 102 2010 325 339
8. S. Motoyama, C.A. Ladines-Llave, S. Luis Villanueva, and T. Maruo The role of human papilloma virus in the molecular biology of cervical carcinogenesis Kobe J. Med. Sci. 50 2004 9 19 (Pubitemid 40136931)
9. M.A. Stanley, M.R. Pett, and N. Coleman HPV: from infection to cancer Biochem. Soc. Trans. 35 2007 1456 1460
10. K. Hellner, and K. Munger Human papillomaviruses as therapeutic targets in human cancer J. Clin. Oncol. 29 2011 1785 1794
11. J.H. Su, A. Wu, E. Scotney, B. Ma, A. Monie, C.F. Hung, and T.C. Wu Immunotherapy for cervical cancer: research status and clinical potential BioDrugs 24 2010 109 129
12. S.H. van der Burg, and C.J. Melief Therapeutic vaccination against human papilloma virus induced malignancies Curr. Opin. Immunol. 23 2011 252 257
13. E.B. Lindblad Aluminium adjuvants - in retrospect and prospect Vaccine 22 2004 3658 3668 (Pubitemid 39106848)
14. K. Lin, K. Doolan, C.F. Hung, and T.C. Wu Perspectives for preventive and therapeutic HPV vaccines J. Formos. Med. Assoc. 109 2010 4 24
15. A. Pashine, N.M. Valiante, and J.B. Ulmer Targeting the innate immune response with improved vaccine adjuvants Nat. Med. 11 2005 S63 S68
16. M. Singh, and D. O'Hagan Advances in vaccine adjuvants Nat. Biotechnol. 17 1999 1075 1081 (Pubitemid 29533545)
17. D.T. O'Hagan Recent developments in vaccine delivery systems M.M. Levine, J.B. Kaper, R. Rappuoli, M. Liu, M.F. Good, New Generation Vaccines 3th ed. 2004 Marcel Dekker Inc. New York 259 270
18. E. Yuba, C. Kojima, A. Harada, Tana, S. Watarai, and K. Kono pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity Biomaterials 31 2010 943 951
19. M.H. Huang, A.H. Chou, S.P. Lien, H.W. Chen, C.Y. Huang, W.W. Chen, P. Chong, S.J. Liu, and C.H. Leng Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly (ethylene glycol)-block-poly (lactide-co-epsilon-caprolactone) J. Biomed. Mater. Res. B Appl. Biomater. 90 2009 832 841
20. M.H. Huang, C.Y. Huang, S.C. Lin, J.H. Chen, C.C. Ku, A.H. Chou, S.J. Liu, H.W. Chen, P. Chong, and C.H. Leng Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine Microbes Infect. 11 2009 654 660
21. M.H. Huang, S.C. Lin, C.H. Hsiao, H.J. Chao, H.R. Yang, C.C. Liao, P.W. Chuang, H.P. Wu, C.Y. Huang, C.H. Leng, S.J. Liu, H.W. Chen, A.H. Chou, A.Y. Hu, and P. Chong Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice PLoS One 5 2010 e12279
22. B.C. Baudner, V. Ronconi, D. Casini, M. Tortoli, J. Kazzaz, M. Singh, L.D. Hawkins, A. Wack, and D.T. O'Hagan MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020) Pharm. Res. 26 2009 1477 1485
23. M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D.T. O'Hagan Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA Pharm. Res. 18 2001 1476 1479 (Pubitemid 32977256)
24. J.S. Thomann, B. Heurtault, S. Weidner, M. Brayé, J. Beyrath, S. Fournel, F. Schuber, and B. Frisch Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting Biomaterials 32 2011 4574 4583
25. C.L. Cooper, H.L. Davis, M.L. Morris, S.M. Efler, M.A. Adhami, A.M. Krieg, D.W. Cameron, and J. Heathcote CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study J. Clin. Immunol. 24 2004 693 701 (Pubitemid 40933121)
26. S.A. Halperin, G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J.J. Eiden A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant Vaccine 21 2003 2461 2467 (Pubitemid 36561337)
27. A.M. Krieg Development of TLR9 agonists for cancer therapy J. Clin. Invest. 117 2007 1184 1194 (Pubitemid 46718403)
28. R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann, and C.V. Harding CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity J. Exp. Med. 186 1997 1623 1631 (Pubitemid 27506276)
29. R.D. Weeratna, M.J. McCluskie, Y. Xu, and H.L. Davis CpG DNA induces stronger immune responses with less toxicity than other adjuvants Vaccine 18 2000 1755 1762 (Pubitemid 30122837)
30. E. Erikci, M. Gursel, and I. Gursel Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes Biomaterials 32 2011 1715 1723
31. C.Y. Huang, J.J. Chen, K.Y. Shen, L.S. Chang, Y.C. Yeh, I.H. Chen, P. Chong, S.J. Liu, and C.H. Leng Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model PLoS One 7 2012 e40970
32. M.H. Huang, C.Y. Huang, S.P. Lien, S.Y. Siao, A.H. Chou, H.W. Chen, C.H. Leng, and P. Chong Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant Pharm. Res. 26 2009 1856 1862
33. J. Aucouturier, L. Dupuis, and V. Ganne Adjuvants designed for veterinary and human vaccines Vaccine 19 2001 2666 2672 (Pubitemid 32234287)
34. S.T. Reddy, M.A. Swartz, and J.A. Hubbell Targeting dendritic cells with biomaterials: developing the next generation of vaccines Trends Immunol. 27 2006 573 579 (Pubitemid 44708833)
35. A. Seubert, S. Calabro, L. Santini, B. Galli, A. Genovese, S. Valentini, S. Aprea, A. Colaprico, U. D'Oro, M.M. Giuliani, M. Pallaoro, M. Pizza, D.T. O'Hagan, A. Wack, R. Rappuoli, and E. De Gregorio Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88 Proc. Natl. Acad. Sci. U. S. A. 108 2011 11169 11174
36. V. Parodi, D. de Florentiis, M. Martini, and F. Ansaldi Inactivated influenza vaccines: recent progress and implications for the elderly Drugs Aging 28 2011 93 106
37. W.E. Beyer, J.J. Nauta, A.M. Palache, K.M. Giezeman, and A.D. Osterhaus Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis Vaccine 29 2011 5785 5792
38. F. Mosca, E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O'Hagan, R. Rappuoli, and E. De Gregorio Molecular and cellular signatures of human vaccine adjuvants Proc. Natl. Acad. Sci. U. S. A. 105 2008 10501 10506
39. X. Zhu, M. Tommasino, K. Vousden, E. Sadovnikava, R. Rappuoli, L. Crawford, M. Kast, C.J. Melief, P.C. Beverley, and H.J. Stauss Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papilloma virus 16 in H-2d mice Scand. J. Immunol. 42 1995 557 563
40. D.T. O'Hagan, M. Ugozzoli, J. Barackman, M. Singh, J. Kazzaz, K. Higgins, T.C. Vancott, and G. Ott Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1 Vaccine 18 2000 1793 1801 (Pubitemid 30122841)
41. + T cell sequestration, dysfunction and deletion Nat. Med. 19 2013 465 472
42. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P. Vloon, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, R. Offringa, S.H. van der Burg, and C.J. Melief Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity Clin. Cancer Res. 14 2008 169 177 (Pubitemid 351377993)
43. G.G. Kenter, M.J. Welters, A.R. Valentijn, M.J. Lowik, D.M. Berends-van der Meer, A.P. Vloon, F. Essahsah, L.M. Fathers, R. Offringa, J.W. Drijfhout, A.R. Wafelman, J. Oostendorp, G.J. Fleuren, S.H. van der Burg, and C.J. Melief Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N. Engl. J. Med. 361 2009 1838 1847
44. C.J. Melief Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus Cancer J. 17 2011 300 301
45. T.T. Beaudette, E.M. Bachelder, J.A. Cohen, A.C. Obermeyer, K.E. Broaders, J.M. Frechet, E.S. Kang, I. Mende, and W.W. Tseng Davidson MG and Engleman EG: in vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines Mol. Pharm. 6 2009 1160 1169
46. A.R. Kammer, M. Amacker, S. Rasi, N. Westerfeld, C. Gremion, D. Neuhaus, and R. Zurbriggen A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses Vaccine 25 2007 7065 7074 (Pubitemid 47464681)
47. Z. Cui, and L. Huang Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer Cancer Immunol. Immunother. 54 2005 1180 1190 (Pubitemid 41416950)
48. W. Chen, W. Yan, and L. Huang A simple but effective cancer vaccine consisting of an antigen and a cationic lipid Cancer Immunol. Immunother. 57 2008 517 530 (Pubitemid 351170535)
49. W. Chen, and L. Huang Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine Mol. Pharm. 5 2008 464 471 (Pubitemid 351929830)
50. M.G. Tovey, and C. Lallemand Adjuvant activity of cytokines Methods Mol. Biol. 626 2010 287 309
51. N. Lapteva, and X.F. Huang CCL5 as an adjuvant for cancer immunotherapy Expert. Opin. Biol. Ther. 10 2010 725 733
52. M.S. Duthie, H.P. Windish, C.B. Fox, and S.G. Reed Use of defined TLR ligands as adjuvants within human vaccines Immunol. Rev. 239 2011 178 196
53. E. Celis Toll-like receptor ligands energize peptide vaccines through multiple paths Cancer Res. 67 2007 7945 7947 (Pubitemid 47395122)
54. J.T. Evans, C.W. Cluff, D.A. Johnson, M.J. Lacy, D.H. Persing, and J.R. Baldridge Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529 Expert Rev. Vaccines 2 2003 219 229 (Pubitemid 36559927)
55. F. Steinhagen, T. Kinjo, C. Bode, and D.M. Klinman TLR-based immune adjuvants Vaccine 29 2011 3341 3355
56. A.C. Steere, V.K. Sikand, F. Meurice, D.L. Parenti, E. Fikrig, R.T. Schoen, J. Nowakowski, C.H. Schmid, S. Laukamp, C. Buscarino, and D.S. Krause Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group N. Engl. J. Med. 339 1998 209 215 (Pubitemid 28350162)
57. N. Garcon, L. Segal, F. Tavares, and M. Van Mechelen The safety evaluation of adjuvants during vaccine development: the AS04 experience Vaccine 29 2011 4453 4459
58. B. Burke, V.R. Gomez-Roman, Y. Lian, Y. Sun, E. Kan, J. Ulmer, I.K. Srivastava, and S.W. Barnett Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits Virology 387 2009 147 156
59. D. Verthelyi, V.W. Wang, J.D. Lifson, and D.M. Klinman CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques AIDS 18 2004 1003 1008 (Pubitemid 38591190)
60. G.J. Weiner CpG oligodeoxynucleotide-based therapy of lymphoid malignancies Adv. Drug Deliv. Rev. 61 2009 263 267
61. A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, L. Puybasset, R. Van Effenterre, J.Y. Delattre, and A.F. Carpentier Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma Neuro. Oncol. 8 2006 60 66 (Pubitemid 43154452)
62. P. Mukherjee, L.B. Pathangey, J.B. Bradley, T.L. Tinder, G.D. Basu, E.T. Akporiaye, and S.J. Gendler MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model Vaccine 25 2007 1607 1618 (Pubitemid 46108207)
63. G. Sen, Q. Chen, and C.M. Snapper Immunization of aged mice with a pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4 +- T-cell priming to young adult levels Infect. Immun. 74 2006 2177 2186
64. C.C. Amaral, I.P. Garcia, G.F. Fernandes, S.R. Almeida, Z.P. Camargo, and M.C. Souza Adjuvant effect of synthetic oligodeoxyribonucleotides (CpG-ODN) from the Paracoccidioides brasiliensis gp43 gene on the Th2-Th1 immunomodulation of experimental paracoccidioidomycosis Scand. J. Immunol. 62 2005 325 333 (Pubitemid 41565384)
65. P. Daftarian, M. Mansour, A.C. Benoit, B. Pohajdak, D.W. Hoskin, R.G. Brown, and W.M. Kast Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine 24 2006 5235 5244 (Pubitemid 43818188)
66. A.G. Chandy, M. Nurkkala, A. Josefsson, and K. Eriksson Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours Vaccine 25 2007 6037 6046 (Pubitemid 47077542)
67. M.L. Cerutti, L.G. Alonso, S. Tatti, and G. de Prat-Gay Long-lasting immunoprotective and therapeutic effects of a hyperstable E7 oligomer based vaccine in a murine human papillomavirus tumor model Int. J. Cancer 130 2012 1813 1820
68. C. Mansilla, P. Berraondo, M. Durantez, M. Martinez, N. Casares, L. Arribillaga, F. Rudilla, J. Fioravanti, T. Lozano, L. Villanueva, P. Sarobe, F. Borras, C. Leclerc, J. Prieto, and J.J. Lasarte Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin Int. J. Cancer 131 2012 641 651